Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders

Voon, Valerie; Fernagut, Pierre‐Olivier; Wickens, Jeff; Baunez, Christelle; Rodrı́guez, Manuel; Pavón, Nancy; Juncos, Jorge L.; Obeso, José A.; Bézard, Erwan

doi:10.1016/s1474-4422(09)70287-x

Cited by 316 publications

(228 citation statements)

References 107 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Bupropion has even been suggested as a potential treatment for SSRI-induced sexual dysfunction or hypoactive sexual desire disorder in women (Modell et al, 2000). This is in line with clinical observations relating dopamine agonists to hypersexuality (Voon et al, 2009) and dopamine antagonists to sexual dysfunction (Baldwin and Mayers, 2003). Animal experiments clearly support the notion that modulation of central, but not peripheral, serotonergic pathways is involved in SSRI-related alteration of sexual functioning (Waldinger et al, 1998).…”

Section: Introductionsupporting

confidence: 87%

“…Dopamine agonists have been shown to induce penile erection in animals and humans (Carson, 2007) and have been suggested as promising agents for the treatment of sexual dysfunction (Albersen et al, 2010). Dopamine agonists have further been related to hypersexuality in the treatment of Parkinson's disease (for review, see Voon et al, 2009). Impaired recruitment of the midbrain was suggested as a correlate of decreased sexual interest in an fMRI study on pedophilia (Walter et al, 2007).…”

Section: Activity Increases Of Subcortical Regions Under Bupropionmentioning

confidence: 99%

See 1 more Smart Citation

Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion

Abler

Seeringer

Hartmann

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs) like paroxetine in the treatment of depression, imposing a considerable risk on medication adherence and hence therapeutic success. Bupropion, a norepinephrine and dopamine reuptake inhibitor, is recommended as an alternative treatment without adverse effects concerning sexual arousal and libido. We investigated the neural bases of paroxetine-related subjective sexual dysfunction when compared with bupropion and placebo. We scanned 18 healthy, heterosexual males in a randomized, double-blind, within-subject design while watching video clips of erotic and nonerotic content under steady-state conditions after taking 20 mg of paroxetine, 150 mg of bupropion, and placebo for 7 days each. Under paroxetine, ratings of subjective sexual dysfunction increased compared with placebo or bupropion. Activation along the anterior cingulate cortex (ACC), including subgenual, pregenual, and midcingulate cortices, in the ventral striatum and midbrain was decreased when compared with placebo. In contrast, bupropion let subjective ratings and ACC activations unchanged and increased activity of brain regions including posterior midcingulate cortex, mediodorsal thalamus, and extended amygdala relative to placebo and paroxetine. Brain regions that have been related to the processing of motivational (ventral striatum), emotional, and autonomic components of erotic stimulation (anterior cingulate) in previous studies showed reduced responsiveness under paroxetine in our study. Drug effects on these regions may be part of the mechanism underlying SSRI-related sexual dysfunction. Increased activation under bupropion may point to an opposite effect that may relate to the lack of impaired sexual functioning.

show abstract

Section: Introductionsupporting

confidence: 87%

Section: Activity Increases Of Subcortical Regions Under Bupropionmentioning

confidence: 99%

Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion

Abler

Seeringer

Hartmann

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Thus, the untreated and treated states of PD represent a model of opposite pathophysiological states linked to dysfunction in BG-thalamocortical loops (Figure 1) [28,29]. Different surgical targets exist for different parkinsonian signs (Table 2) [30,31].…”

Section: Reviewmentioning

confidence: 99%

Deep brain stimulation in Parkinson disease—what went wrong?

Krack

Hariz

2010

Nat Rev Neurol

View full text Add to dashboard Cite

“…La stimulation cé ré brale profonde est utilisé e afin de traiter la maladie de Parkinson (Limousin et al, 1995 ;Voon et al, 2009) et les dé pressions sé vè res ré sistantes aux mé dicaments (Lozano et al, 2008 ;Holtzheimer et Mayberg, 2010). Cependant, ces techniques ne sont pratiqué es que dans les cas extrê mes ré sistants aux traitements mé dicamenteux chez les patients atteints de la maladie de Parkinson et sont encore au stade expé rimental pour les patients souffrant de dé pression sé vè re (Bewernick et al, 2012).…”

Section: Introductionunclassified

La stimulation transcrânienne à courant continu : un nouvel outil de neurostimulation

Thibaut¹,

Chatelle²,

Gosseries³

et al. 2013

Revue Neurologique

View full text Add to dashboard Cite

Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders

Cited by 316 publications

References 107 publications

Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion

Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion

Deep brain stimulation in Parkinson disease—what went wrong?

La stimulation transcrânienne à courant continu : un nouvel outil de neurostimulation

Contact Info

Product

Resources

About